Background
==========

Acute myeloid leukemia (AML) is a heterogeneous group of diseases characterized by increasing immature progenitors in the bone marrow and peripheral blood. The leukemic subtypes are crucial to treatment and prognosis. Immunophenotyping by flow cytometry has been extensively used for the diagnosis and classification of acute leukemia \[[@B1],[@B2]\]. Detection of leukemia-associated immunophenotypes by flow cytometry is also recognized as an important tool in monitoring minimal residual disease and predicting clinical outcome \[[@B3]-[@B5]\]. Karyotype is another important prognostic factor by which AML patients can be stratified into good-, intermediate-, and poor-risk groups. Leukemic blasts in AML with recurrent cytogenetic abnormalities, such as t(8;21), t(15;17), and inv(16) show specific antigen expression patterns \[[@B6]\]. Recently, an association of *CEBPA* mutation with a distinct immunophenotype was also reported \[[@B7]\].

About 40%-50% of AML patients have a normal karyotype of leukemic cells, and one-half of these patients have mutations of nucleophosmin (*NPM1)*\[[@B8],[@B9]\], which encodes a shuttle protein transporting continuously between the nucleus and cytoplasm \[[@B10]\]. *NPM1* mutations are usually associated with absence of HLA-DR and CD34 expression \[[@B11]\]; however, the surface marker expression in blasts varies in individual AML patients and the clinical implication of immunophenotype in this subtype of AML remains unclear. Previous reports have suggested that expression of some surface antigens is correlated with clinical outcome in AML patients \[[@B12]-[@B14]\], but the prognostic significance of immunophenotype is still an issue of controversy \[[@B15],[@B16]\]. Most studies analyzed the prognostic implication of individual antigens, and usually in a heterogeneous population of AML patients with various genetic abnormalities. In this study, we performed a hierarchical cluster analysis of the immunophenotype expression profiles in a relatively homogeneous cohort of AML patients with *NPM1* mutations, and correlated the results with clinical characteristics, other gene mutations, and prognoses.

Methods
=======

Patients
--------

Five hundred forty-three patients diagnosed as having *de novo* AML at the National Taiwan University Hospital between 1987 and 2007 were recruited in this study as the investigation cohort. In order to confirm the prognostic implication of the immunophenotypic profile, another 36 AML patients diagnosed with *NPM1* mutation between 2008 and 2010 were enrolled as the validation cohort. The informed consents were collected from all living patient. The NPM1 mutation was retrospectively checked in part of patients. Cryopreserved samples were collected from marrow bank according to the criteria of local ethics committee. This research conformed to the Helsinki Declaration and was approved by the National Taiwan University Hospital Research Ethics Committee.

Immunophenotype
---------------

A panel of monoclonal antibodies, including HLADR, CD2, CD7, CD11b, CD13, CD14, CD15, CD19, CD33, CD34, CD41a, and CD56, was used to characterize the phenotypes of the leukemic cells as previously described \[[@B11]\].

Cytogenetic analysis
--------------------

Cytogenetic analysis was performed as described previously \[[@B17]\]. Briefly, the bone marrow and/or peripheral blood cells were harvested either directly or after 1--3 days of culture. Metaphase chromosomes were banded by the conventional trypsin-Giemsa banding technique and karyotyped according to ISCN \[[@B18]\].

Gene mutation analysis
----------------------

Mononuclear cells obtained from bone marrow aspirates were isolated by Ficoll-Hypaque gradient centrifugation and cryopreserved. Genomic DNAs were extracted and amplified by Illustra GenomiPhi V2 DNA amplification kit as described by the manufacturer (GE Healthcare). The primer design was according to the previous study \[[@B7],[@B11],[@B19]-[@B21]\]. Analysis of *NPM* exon 12 mutation was done as described by Falini et al. \[[@B8],[@B11]\]. Briefly, the final volume for PCR reaction was 35 μL containing 200 ng DNA, 200 nmol/L deoxynucleotide triphosphate, 2 mmol/L MgSO~4~, 140 nmol/L of each primer, and 1 unit of AmpliTaq Gold polymerase (Applied Biosystems, Foster City, CA). PCR was done by heating at 95°C for 10 minutes, followed by 35 cycles of 95°C for 45 seconds, 49°C for 1 minute, and 72°C for 1 minute, with a final step for 10 minutes at 72°C. PCR products were electrophoresed on 2% agarose gels, purified and sequenced using the BigDye Terminator v3.1 Cycle Sequencing kit, which contained AmpliTaq DNA polymerase FS (Applied Biosystems), on an automated ABI-3100 Genetic Analyzer (Applied Biosystems). Abnormal sequencing results were confirmed by at least two repeated analyses. Analysis of the gene mutations of *CEBPA*\[[@B7]\]*, MLL-ITD*\[[@B19]\]*, WT1*\[[@B20]\]*, FLT3-ITD, FLT3-TKD, JAK2, PTPN11*, *NRAS,* and *KRAS*\[[@B21]\] was performed by polymerase chain reaction and direct sequencing. Abnormal sequencing results were confirmed by at least two repeated analyses.

Statistics
----------

Comparisons between groups were made with the ANOVA and chi-square tests. Hierarchical cluster analysis was performed with an agglomeration schedule, and the cluster distance was expressed as the Binary Square Euclidean distance \[[@B22],[@B23]\]. A dendrogram was plotted using the average linkage method. Survival curves were plotted by the Kaplan-Meier method; differences between the curves were analyzed by the log-rank test. Multivariate Cox regression analysis was used to investigate independent prognostic factors for overall survival and relapse free survival. All statistical analyses were performed with SPSS 18.0 for Windows (SPSS, Inc., Chicago, IL, USA). Values of *P \<* 0.05 were considered significant.

Results
=======

Clinical characteristics of patients with *NPM1* gene mutations
---------------------------------------------------------------

The clinical and laboratory data of the 543 AML patients are shown in Table [1](#T1){ref-type="table"}. There were 315 men and 228 women with a median age of 48 years; 52 patients were children less than 18 years and 491 were adults. *NPM1* gene mutations were detected in 108 (19.8%) of AML patients overall, and in 90 (37.5%) of the 241 AML patients with a normal karyotype, which were in agreement to our previous report \[[@B11]\]. *NPM1* gene mutations were rarely detected in children (2/52 (3.8%) in children vs. 106/491 (21.2%) in adults, p \< 0.001). Females had a higher incidence of *NPM1* mutations than males (25.4% vs. 15.9%, p \< 0.001). *NPM1* mutations were closely associated with HLA-DR(−), CD33(+), and CD34(−) (p \< 0.001 for all three markers, Table [1](#T1){ref-type="table"}).

###### 

**Clinico-laboratory characteristics in AML patients with*NPM1*mutations**

                         **Total AML patients (n = 543)**   **AML patients with*NPM1*mutation (n = 108)**   **AML patients with wild type*NPM1*(n = 435)**   **P-Value**
  --------------------- ---------------------------------- ----------------------------------------------- ------------------------------------------------ -------------
         Age^\#^                                                                                                                                                0.001
    Adult(\>18 years)                  491                                    106(21.6)                                       385(78.4)                            
         Children                       52                                     2(3.8)                                          50(96.2)                            
       Gender^\#^                                                                                                                                               0.007
           Male                        315                                    50(15.9)                                        265(84.1)                            
          Female                       228                                    58(25.4)                                        170(74.6)                            
     Laboratory data                                                                                                                                               
         WBC(uL)                      20660                                     38860                                           14260                           0.002
    Hemoglobin (g/dL)                  8.1                                       8.4                                             8.0                            0.095
       Platelet(uL)                   43000                                     52000                                           40000                           0.865
      LDH (units/L)                    861                                      1068                                             826                            0.149
     FAB subtype^\#^                                                                                                                                            0.008
            M0                          10                                      0(0)                                           10(100)                             
            M1                         120                                    23(19.2)                                         97(80.8)                            
            M2                         184                                    40(21.7)                                        144(78.3)                            
            M3                          40                                      0(0)                                           40(100)                             
            M4                         131                                    34(26.0)                                         97(74.0)                            
            M5                          33                                    10(30.3)                                         23(69.7)                            
            M6                          11                                     1(9.1)                                          10(90.9)                            
            M7                          3                                       0(0)                                            3(100)                             
       Undetermined                     5                                       0(0)                                            5(100)                             
    Cytogenetic^\#^\*                                                                                                                                          \<0.001
     Normal karyotype                  241                                    90(37.3)                                        151(62.7)                            
    Abnormal karyotype                 283                                     13(4.6)                                        270(95.4)                            
   Immunophenotype\*\*                                                                                                                                             
          HLA-DR                     364/515                                50/105(47.6)                                    314/410(76.6)                      \<0.001
           CD7                       100/511                                16/104(15.4)                                     84/407(20.6)                       0.269
           CD13                      481/519                                96/105(91.4)                                    385/414(93.0)                       0.536
           CD14                       70/503                                18/104(17.3)                                     52/399(13.0)                       0.267
           CD15                      237/511                                46/104(44.2)                                    191/407(46.9)                       0.660
           CD33                      472/518                                105/105(100)                                    367/413(88.9)                      \<0.001
           CD34                      328/514                                22/104(21.1)                                    306/410(74.6)                      \<0.001
           CD56                      109/457                                 19/95(20.0)                                     90/362(24.9)                       0.347

\*Only 524 patients had cytogenetic data.

\*\* Number of patients with positive expression/number of patients studied.

^\#^Number of patients (%).

Hierarchical cluster analysis of immunophenotypes in patients with *NPM1* gene mutations
----------------------------------------------------------------------------------------

Hierarchical cluster analysis was performed based on the expression profile of 8 surface markers (HLADR, CD34, CD13, CD33, CD7, CD14, CD15, and CD56). The clustering result is displayed by the Treeview dendrogram (Figure [1](#F1){ref-type="fig"}). The rows represented individual cases and the columns were the results of expression of individual surface markers. The blue color indicates positive expression and the yellow color indicates negative expression. Ninety-four patients with *NPM1* mutations and complete immunophenotype data were enrolled in the hierarchical cluster analysis. The clustering analysis divided the patients with *NPM1* mutations into two groups, designated as group I (n = 82, 87%; blue color) and group II (n = 12, 13%; green color), based on the expression profiles of the immunophenotype (Figure [1](#F1){ref-type="fig"}). Leukemic cells from most group I patients were CD34(−)/CD7(−)/CD13(+)/CD33(+), but with variable expression of HLA DR and other antigens, while those from almost all group II patients were HLA DR(+)/CD34(+)/CD7(+)/CD13(+)/CD33(+); only one group II patients showed absence of CD34 on leukemic cells.

![**Hierarchical cluster analysis of 94*NPM1-*mutated patients.**](1471-2407-13-107-1){#F1}

Correlation of immunophenotypic cluster with clinico-laboratory features, associated gene mutations, and clinical outcome
-------------------------------------------------------------------------------------------------------------------------

The clinico-laboratory characteristics of groups I and II are shown in Table [2](#T2){ref-type="table"}. Group II patients had a higher platelet count than group I patients (P \< 0.001), but there were no other differences in parameters between the two groups. We determined 11 other gene mutations, including *FLT3-*ITD*, FLT3-*TKD*, CEBPA, MLL-*PTD*, KIT, JAK2, PTPN11*, *WT1*, *NRAS,* and *KRAS* mutations in patients with *NPM1* mutations*.* Group II patients had a higher frequency of *FLT3-*ITD. There was no association between immunophenotypic cluster and other gene mutations. The COOH-terminal nucleotide changes of *NPM1*gene were also checked, but not correlated to the immunophenotypic cluster.

###### 

**Comparison of clinical-laboratory characteristics between cluster group I and II patients with*NPM1*mutated AML**^**\#**^

                                **Cluster group I (n = 82)**   **Cluster group II (n = 12)**   **P-Value**
  ---------------------------- ------------------------------ ------------------------------- -------------
              Age                                                                                 1.000
        Adult(\>18 years)                    81                             12                       
            Children                         1                               0                       
             Gender                                                                               1.000
              Male                           38                              6                       
             Female                          44                              6                       
        Laboratory data                                                                              
             WBC(uL)                       35710                           43580                  0.409
        Hemoglobin (g/dL)                   8.5                             8.5                   0.710
          Platelet(uL)                     49000                           79000                 \<0.001
          LDH (units/L)                     1056                           1253                   0.803
          FAB subtype                                                                             0.173
               M0                            0                               0                       
               M1                            17                              0                       
               M2                            26                              7                       
               M3                            0                               0                       
               M4                            28                              5                       
               M5                            10                              0                       
               M6                            1                               0                       
               M7                            0                               0                       
          Undetermined                       0                               0                       
          Cytogenetic                                                                             0.662
        Normal karyotype                     67                             10                       
       Abnormal karyotype                    10                              2                       
   Associated gene mutation\*                                                                        
           *FLT3-*ITD                      36(44)                         10(83)                  0.013
           *FLT3-*TKD                      12(15)                          1(8)                   1.000
             *NRAS*                        9(11)                           3(25)                  0.179
             *KRAS*                          0                               0                     NA
            *PTPN11*                        7(9)                             0                    0.589
              *KIT*                          0                               0                     NA
             *JAK2*                          0                               0                     NA
            *MLL-*PTD                        0                               0                     NA
              *WT1*                         2(2)                             0                    1.000
             *CEBPA*                        4(4)                             0                    1.000
      Immunophenotype\*\*                                                                            
             HLA-DR                        34(41)                         12(100)                \<0.001
               CD7                          3(4)                          12(100)                \<0.001
              CD13                         76(93)                         12(100)                 1.000
              CD14                         16(20)                          2(17)                  1.000
              CD15                         36(47)                          5(42)                  1.000
              CD33                        82(100)                         12(100)                 1.000
              CD34                         9(11)                          11(92)                 \<0.001
              CD56                         19(23)                            0                    0.117

Abbreviation: *ITD*, internal tandem duplication; *TKD*, tyrosine kinase domain mutation; *PTD*, partial tandem duplication; *NA*: not application.

^\#^Only 94 patients had complete immunophenotyping data and can be stratified by clustering analysis.

\* Number of patients (% of patients with this gene mutation in each cluster group).

\*\*Numbers of patients (% of patients with this antigen expression in each cluster group).

All four patients with CEBPA mutation were mono-allelic.

Ninety-four patients were recruited in cluster analysis of immunophenotype. There were 31 patients who received supportive care alone due to old age and frailty. Sixty-three patients were treated with standard intensive chemotherapy of idarubicin 12 mg/m^2^ per day on days 1--3 and cytarabine 100 mg/m^2^ per day on days 1--7 and then 2--4 courses of consolidation chemotherapy with high-dose cytarabine (2000 mg/m^2^ q12 h days 1--4, total 8 doses), with or without one anthracycline after complete remission (CR) was achieved. Eight patients died following induction chemotherapy, and eleven patients received HSCT and their disease free survival was censored at the time of transplantation.

With a median follow-up time of 53 months, the group II patients had a significantly shorter relapse-free survival (RFS; median, 3 vs. 23 months; p = 0.006; Figure [2](#F2){ref-type="fig"}) and overall survival (OS; median, 11 vs. 40 months; p = 0.02; Figure [2](#F2){ref-type="fig"}) than group I patients. For practicality, we compared the outcome of patients with positivity for all HLA-DR, CD34, and CD7 (n = 11) with that of other patients (n = 83); it was also shown that the former groups had a significantly worse prognosis than the latter group (RFS, *p* = 0.006; OS, *p* = 0.02).

![**Kaplan-Meier survival curves of relapse-free survival (RFS, left curve) and overall survival (OS, right curve) of 94*NPM1-*mutated patients stratified by immunophenotypic clustering profile.**](1471-2407-13-107-2){#F2}

We performed Cox regression multivariate analysis of variables, including clinico-laboratory data (age, gender, white blood cell count, hemoglobin level, platelet count, lactic dehydrogenase level, FAB subtype), cytogenetics, gene mutations, and immunophenotypic cluster (Table [3](#T3){ref-type="table"}). The multivariate analysis revealed that immunophenotypic cluster was an independent prognostic factor (RFS, *p* \< 0.001; OS, *p* = 0.001) in AML patients with *NPM1* mutations.

###### 

**Multivariate cox regression of prognostic factors in*NPM1*-mutated patients**

                        **Factor**                        **Relapse-free survival (RFS) p-value**   **Odd Ratio**    **95% CI**    **Overall survival (OS) p-value**   **Odd Ratio**    **95% CI**
  ------------------------------------------------------ ----------------------------------------- --------------- -------------- ----------------------------------- --------------- --------------
                 Elderly(Age \> 60 year)                                   0.015                        0.933       0.056-15.647                 0.629                      NA              NA
                 Gender (Male vs Female)                                   0.558                         NA              NA                      0.871                      NA              NA
      Immunophenotypic cluster (Group II vs Group I)                      \<0.001                       2.190       0.363-13.219                 0.001                    10.435       1.217-89.461
                  White blood cell count                                   0.371                         NA              NA                      0.898                      NA              NA
                        Hemoglobin                                         0.836                         NA              NA                      0.349                      NA              NA
                         Platelet                                          0.590                         NA              NA                      0.237                      NA              NA
                  Lactate dehydrogenase                                    0.141                         NA              NA                      0.942                      NA              NA
   Cytogenetic\* (Normokaryotype vs Additional changes)                    0.597                         NA              NA                      0.464                      NA              NA
           CEBPA mutation (mutant vs wild type)                            0.982                         NA              NA                      0.309                      NA              NA
              FLT3-ITD (mutant vs wild type)                              \<0.001                       2.243       0.798-6.306                  0.387                      NA              NA
              FLT3-TKD (mutant vs wild type)                               0.191                         NA              NA                      0.135                      NA              NA

*NA*, not applicable, Cytogenetics\*: The cytogenetic data includes 91 patients with normal karyotype, 12 patients with additional changes, and 5 patients showed no mitosis.

Hierarchical cluster analysis and survival analysis in validation cohort
------------------------------------------------------------------------

In order to confirm the above finding of the prognostic value of immunophenotypic clusters, we collected another cohort of 36 AML patients with *NPM1* mutation diagnosed between 2008 and 2010. This validation cohort comprised 21 women and 15 men, with a median age of 59 years (range 18 to 84). The clinical characteristics were similar between these two cohorts, including age, gender, white blood cell count, hemoglobin level, platelet count, and serum lactate dehydrogenase level. Hierarchical cluster analysis also showed two distinct clusters. Group I patient showed significant better relapse free survival (median: 19.5 months vs. 10.5 months, p = 0.021), and overall survival (median: 32 months vs. 13 months, p = 0.055, Additional file [1](#S1){ref-type="supplementary-material"}: Figure S1). This finding confirmed that *NPM1-*mutated AML patients of immunophenotypic cluster group had worse prognosis.

To further evaluate the significance of immunophenotypic cluster in the prognostic implication of *NPM1*-mutated AML, we incorporated both immunophenotypic cluster and the status of FLT3-ITD into survival analysis in a total 130 *NPM1*-mutated patients. Combined *FLT3-ITD* and immunophenotypic cluster could stratify these patients into distinct group (RFS, p \< 0.001; OS, p = 0.017). The Kaplan-Meier survival curves of relapse free survival and overall survival are shown in Figure [3](#F3){ref-type="fig"}.

![**Kaplan-Meier survival curves of relapse-free survival (left) of all 130*NPM1-*mutated patients stratified by immunophenotypic clustering profile and FLT3 ITD mutation.**(p \< 0.001). Kaplan-Meier survival curves of overall survival (right) of all 130 *NPM1-*mutated patients stratified by immunophenotypic clustering profile and FLT3 ITD mutation. (p = 0.017).](1471-2407-13-107-3){#F3}

Discussion
==========

Immunophenotype analysis is highly helpful for the diagnosis and monitoring of minimal residual disease in hematologic malignancies \[[@B3]-[@B5]\]. Though leukemic blasts from *NPM1-*mutated AML usually show a specific immunophenotype with expression of CD13 and CD33 but absence of CD34 and HLA-DR \[[@B11]\], different expression patterns of surface markers on leukemic cells from individual patients are frequently seen \[[@B24]\]. In this cohort study, hierarchical cluster analysis revealed two distinct immunophenotypic clusters in *NPM1*-mutated patients. Most patients in group I showed CD7(−) CD33(+) CD34(−), while almost all patients in group II expressed HLA-DR, CD7, CD33, and CD34 on leukemic cells. The patients in immunophenotypic cluster group II had poorer outcomes than cluster group I, and the immunophenotypic cluster was an independent prognostic factor.

Some AML subtypes showed specific immunophenotypic patterns of leukemic cells, such as coexpression of CD15, CD34 and sometimes, CD19 in AML with t(8;21); coexpression of CD13, CD33 in absence of CD34 and HLA-DR in AML with t(15;17) \[[@B4]-[@B6]\]; and coexpression of CD34, HLA-DR, CD15 and CD7 in AML with *CEBPA* mutation \[[@B7]\]. The prognostic implication of immunophenotype in AML remains controversial \[[@B15],[@B16]\]. For example, the negative prognostic effect of CD34 expression has been reported in some studies \[[@B25],[@B26]\], but not in others \[[@B27],[@B28]\]. The same is also true for CD7 expression. Most studies analyzed the correlation of the expression of a single marker with clinico-laboratory characteristics in a rather heterogeneous group of AML patients. In this study, the immunophenotypic cluster profiles were analyzed in a relatively homogeneous population of AML patients. Immunophenotypic cluster profiles provided distinct prognostic information in *NPM1*-mutated AML patients.

There are several large studies of *NPM1 mutation* in AML; the presence of *FLT3-ITD* is shown to be a poor prognostic factor in *NPM1*-mutated patients \[[@B29],[@B30]\]. In order to clarify the association of the immunophenotypic patterns of *NPM1*-mutated AML with other gene mutations in AML, we checked class I (*FLT3*-ITD*, FLT3-*TKD*, PTPN11, JAK2, KIT, NRAS, KRAS,* and *WT1*) and class II gene mutations (*CEBPA* and *MLL-PTD*). Although the patients in immunophenotypic cluster group II had a higher incidence of *FLT3*-ITD, a mutation associated with poor prognosis \[[@B31]\], Cox regression multivariate analysis revealed that the immunophenotypic cluster was an independent prognostic factor (RFS, p \< 0.001; OS, p = 0.001) in AML patients with *NPM1* mutations. To further evaluate whether the data of flow cytometry could be directly applied for prognostic prediction in clinical practice, we compared the survival between the patients with expression of all HLA-DR, CD34 and CD7 on leukemic cells and other patients. We found that positivity of all three markers was associated with shorter RFS and OS (*p* = 0.006 and 0.02, respectively). So, it may be worthwhile to use the expression pattern of these three antigens obtained from flow cytometry to predict the survival of patients at diagnosis.

Immunophenotypic cluster in *NPM1*-mutated AML patients has not been described before. In order to confirm the prognostic effect of the immunophenotypic cluster, we validated the correlation of immunophenotypic cluster and clinical outcome in another cohort of 36 *NPM1*-mutated patients diagnosed between 2008 and 2010. Hierarchical cluster analysis also showed two distinct clusters, group I patient showed significant better RFS (median: 19.5 vs. 10.5 months, p = 0.021) and OS (median: 32 months vs. 13 months, p = 0.055). This study was limited to a single university hospital, so the prognostic effect of immunophenotypic cluster should be further validated. Recently, *IDH1, IDH2* and *DNMT3A* mutations have also been reported in AML patients with *NPM1* mutation \[[@B32]-[@B34]\]. Correlating the immunophenotypic cluster with new biomarkers may also provide more insight into the molecular mechanisms of leukemogenesis in the future.

Conclusions
===========

In summary, hierarchical cluster analysis of the immunophenotypic profile was able to separate AML patients with *NPM1* gene mutations into two distinct groups with different prognosis. The immunophenotypic cluster with HLA-DR(+) CD34(+) CD7(+) is a poor prognostic factor independent of *FLT3-ITD* in AML patients with *NPM1* mutations.
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